Synonymous EGFR variant p.Q787Q is neither prognostic nor predictive in patients with lung adenocarcinoma.

Leichsenring J1, Volckmar AL1, Magios N2, Morais de Oliveira CM1, Penzel R1, Brandt R1, Kirchner M1, Bozorgmehr F2, Thomas M2,3, Schirmacher P1,4, Warth A1,3, Endris V1, Stenzinger A1,5,4.

Author information

Abstract

Patients with non-small cell lung cancer (NSCLC) harboring activating mutations in the Epidermal Growth Factor Receptor (EGFR) benefit from targeted therapies. A synonymous polymorphism (rs1050171, p.Q787Q) was shown to be associated with improved overall survival (OS) in colorectal cancer patients. As data in NSCLC are limited, we retrospectively analyzed associations of p.Q787Q with clinicopathological parameters including clinical response and outcome in patients with lung adenocarcinoma (ADC) who received tyrosine kinase inhibitor (TKI) therapy. Of 642 ADC patients whose tumors were profiled by next generation sequencing, 102 (15.9%) carried EGFR mutations targetable by TKIs (30.4% male patients, median age 65.1 y, 19.6% smokers with 12.8 median pack years). Seventy-nine patients (77.5%) received TKI therapy either as a first- or second-line therapy. Of the 102 EGFR-mutant tumors, 72 (70.6%) exhibited the p.Q787Q polymorphism and another 12 (11.8%) cases with p.Q787Q harbored an additional TKI insensitive mutation (p.T790M). The polymorphism was neither associated with classic clinicopathological parameters nor with overall survival (21.1 months vs. 20.1 months; P-value = 0.91) or clinical response (P-value = 0.122). The patients with p.T790M had worse survival compared to EGFR activating mutation carriers with and without p.Q787Q when analyzed as a separate group (27.5 months, P-value = 0.02). In conclusion, p.Q787Q is neither a suitable prognostic nor predictive biomarker for ADC patients receiving anti-EGFR therapy in first- or second-line of therapy. © 2016 Wiley Periodicals, Inc.

PMID:: 27750395
DOI:: 10.1002/gcc.22427

[PubMed - in process]

Colorectal Cancer Genomics

- Cancer PHGKB -

From HuGE Literature Finder Database

This database contains published literature on genetic associations and other human genome epidemiology

Synonymous EGFR variant p.Q787Q is neither prognostic nor predictive in patients with lung adenocarcinoma.
Genes, chromosomes & cancer 2017 Mar 56 (3): 214-220.
Leichsenring Jonas, Volckmar Anna-Lena, Magios Nikolaus, Morais de Oliveira Cristiano Manuel, Penzel Roland, Brandt Regine, Kirchner Martina, Bozorgmehr Farastuk, Thomas Michael, Schirmacher Peter, Warth Arne, Endris Volker, Stenzinger Albrec
Chromosome 20q Amplification Defines a Subtype of Microsatellite Stable, Left-sided Colon Cancers with Wild-type RAS/RAF and Better Overall Survival.
Molecular cancer research : MCR 2017 Feb .
Ptashkin Ryan N, Pagan Carlos, Yaeger Rona, Middha Sumit, Shia Jinru, O'Rourke Kevin P, Berger Michael F, Wang Lu, Cimera Robert, Wang Jiajing, Klimstra David S, Saltz Leonard, Ladanyi Marc, Zehir Ahmet, Hechtman Jaclyn
High-risk epithelial ovarian cancer patients for hereditary ovarian cancer.
The journal of obstetrics and gynaecology research 2017 Feb .
Chirasophon Seksit, Manchana Tarinee, Teerapakpinyo Chinacho
IRS-2 rs1805097 polymorphism is associated with the decreased risk of colorectal cancer.
Oncotarget 2017 Feb .
Yin Jiefeng, Zhang Zhe, Zheng Huajun, Xu L
Molecular profiling of metastatic colorectal tumors using next-generation sequencing: A single-institution experience.
Oncotarget 2017 Feb .
Gong Jun, Cho May, Sy Marvin, Salgia Ravi, Fakih Marw